Anticancer drug dose individualisation: From body surface area to physiology;Pourquoi individualiser les doses de médicaments anticancéreux: De la surface corporelle à la physiologie

Bulletin du Cancer

Volumn 95, Issue 10, 2008, Pages 895-901

  Pétain, Aurélie ^a   Chatelut, Étienne ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Body surface area; Pharmacokinetics; Renal function; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUOROURACIL; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; TENIPOSIDE;

BODY SURFACE; CANCER LOCALIZATION; DOSE CALCULATION; DRUG EFFICACY; DRUG ELIMINATION; KIDNEY FUNCTION; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BODY SIZE; BODY SURFACE AREA; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; NEOPLASMS;

EID: 56149127749     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0720     Document Type: Review

References (40)

1. Gurney H. Dose calculations of anticancer drugs : a review of the current practice and introduction of an alternative. J Clin Oncol 1996 ; 14 : 2590-611.
2. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998 ; 56 : 1019-38.
3. Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Fety-Deporte R, et al. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 2000 ; 68 : 270-9.
4. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966 ; 50 : 219-44.
5. Homan ER. Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man. Cancer Chemother Rep 1972 ; 3 : 13-9.
6. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970 ; 54 : 225-35.
7. Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003 ; 21 : 197-202.
8. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 1990 ; 82 : 323-5.
9. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002 ; 94 : 1883-8.
10. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007 ; 25 : 4707-13.
11. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000 ; 58 : 944-58.
12. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage : prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 ; 7 : 1748-56.
13. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 2003 ; 146 : 95-158.
14. Ito K, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SP. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 2001 ; 276 : 38108-14.
15. Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005 ; 15 : 277-85.
16. Robert J, Le Morvan V. Bases biologiques de l'individualisation des prescriptions en oncologie : le génome constitutionnel. Bull Cancer 2008 : 95.
17. Laurent-Puig P, Lièvre A, Ducreux M, Loriot MA. Le point de vue du biologiste sur la pharmacogénétique dans le cancer colorectal. Bull Cancer 2008 : 95.
18. Ducreux M, Laurent-Puig P. Individualisation des prescriptions dans le cancer colorectal. Le point de vue du clinicien. Bull Cancer 2008 : 95.
19. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976 ; 16 : 31-41.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine : a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 ; 130 : 461-70.
21. Seronie-Vivien S, Galteau MM, Carlier MC, Hadj-Aissa A, Hanser AM, Hym B, et al. Impact of standardized calibration on the inter-assay variation of 14 automated assays for the measurement of creatinine in human serum. Clin Chem Lab Med 2005 ; 43 : 1227-33.
22. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996 ; 14 : 3062-73.
23. Launay-Vacher V, Chatelut E, Lichtman SM, Wildiers H, Steer C, Aapro M. Renal insufficiency in elderly cancer patients : International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007 ; 18 : 1314-21.
24. Thomas F, Seronie-Vivien S, Malard L, Chatelut E. Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys. Therapie 2007 ; 62 : 121-7.
25. Chatelut E, Canal P, Bugat R. Pharmacokinetics and individual dose adjustment of carboplatin. Bull Cancer 2000 ; 87(Spec Iss.) : 17-23.
26. Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, et al. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular non-seminomatous germ cell tumors. J Clin Oncol 1991 ; 9 : 62-9.
27. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992 ; 10 : 520-8.
28. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, et al. Cyclophosphamide pharmacokinetics : correlation with cardiac toxicity and tumor response. J Clin Oncol 1992 ; 10 : 995-1000.
29. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986 ; 81 : 387-94.
30. Desoize B, Maréchal F, Cattan A. Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. Br J Cancer 1990 ; 62 : 840-1.
31. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994 ; 12 : 1291-5.
32. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989 ; 7 : 1816-23.
33. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994 ; 343 : 1188-90.
34. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986 ; 314 : 471-7.
35. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996 ; 97 : 73-80.
36. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994 ; 12 : 1443-51.
37. Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, BriasouUs E, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients : a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007 ; 13 : 6410-8.
38. Rodman JH, Abromowitch M, Sinkule JA, Hayes FA, Rivera GK, Evans WE. Clinical pharmacodynamics of continuous infusion teniposide : systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987 ; 5 : 1007-14.
39. Ferrero JM, Chamorey E, Magne N, Leccia F, Largillier R, Namer M, et al. The raltitrexed-vinorelbine combination : a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. Cancer Chemother Pharmacol 2002 ; 50 : 459-64.
40. Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics : the influence of genomic variation on drug response. Curr Top Med Chem 2004 ; 4 : 1399-409.